NCT02975973

Brief Summary

Cognitive impairments in schizophrenia are the most debilitating aspect of the illness and poorly treated by current medications. This study investigates transcranial direct current stimulation (tDCS) - a safe, noninvasive weak electrical current delivery to stimulate brain function - as a novel therapeutic for cognition in schizophrenia. Integrating neurostimulation, electrophysiology and neuroimaging, this project aims to study tDCS effects on cognition by verifying therapeutic target engagement, evaluating the tolerability of tDCS sessions, and optimizing treatment parameters.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable schizophrenia

Timeline
Completed

Started Nov 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2016

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

November 23, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 29, 2016

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2019

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

November 25, 2020

Completed
Last Updated

November 25, 2020

Status Verified

November 1, 2020

Enrollment Period

2.6 years

First QC Date

November 23, 2016

Results QC Date

June 29, 2020

Last Update Submit

November 4, 2020

Conditions

Keywords

tDCScognitive controlEEGgamma oscillations

Outcome Measures

Primary Outcomes (2)

  • tDCS Engagement of DLPFC Activity Indexed by fMRI BOLD Imaging

    Change from Baseline to week 1 as measured by modulation of fMRI BOLD signal in DLPFC in the context of cognitive control task performance.

    1 week

  • tDCS Engagement of DLPFC Activity Indexed by Modulation of Frontal Cortical Gamma Oscillations

    Change from Baseline to week 1 as measured by EEG frontal gamma oscillations in the context of cognitive control task performance

    1 week

Secondary Outcomes (2)

  • Optimal tDCS Strength for DLPFC Engagement

    1 Week

  • Tolerability and Feasibility of Multi-session tDCS in Schizophrenia

    1 week

Study Arms (4)

2.5mA

EXPERIMENTAL

Active stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.

Device: transcranial direct current stimulation

2.0mA

EXPERIMENTAL

Active stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.

Device: transcranial direct current stimulation

1.5mA

EXPERIMENTAL

Active stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.

Device: transcranial direct current stimulation

0mA

SHAM COMPARATOR

This will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.

Device: transcranial direct current stimulation

Interventions

transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.

0mA1.5mA2.0mA2.5mA

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • ages 18-35 years;
  • within first five years of antipsychotic treatment;
  • on stable doses of antipsychotic medication for at least one month;
  • Clinically stable as defined by Clinical Global Impression-Severity scale (CGI-S) less than or equal to 4 (moderately ill);
  • Mild to severe cognitive impairment in MATRICS Consensus Cognitive Battery (composite scores \<40);
  • DSM-5 MINI 7.0.2 criteria for schizophrenia or schizoaffective by patient SCID

You may not qualify if:

  • Mental retardation as defined by pre-morbid IQ by Wechsler Test of Adult Reading at screening \<70 or Spanish Word Accentuation Test;
  • significant head injury;
  • History of severe medical or neurological illnesses
  • pregnancy or postpartum (\<6 weeks after delivery or miscarriage);
  • inability to provide informed consent;
  • significant color blindness that affects task performance;
  • Positive urine drug screen (exception for marijuana) or presence of substance use disorder within 1 month;
  • Currently on benzodiazepines or mood stabilizers affecting GABA

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Baylor College of Medicine

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

SchizophreniaPsychotic Disorders

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Limitations and Caveats

Despite concerted and exhaustive subject recruitment efforts, the total number of patients completing the protocol was minimal. As such the sample size was inadequate for deriving any meaningful descriptive statistics or statistical comparisons.

Results Point of Contact

Title
Raymond Cho
Organization
Baylor College of Medicine

Study Officials

  • Raymond Cho, M.D., M.Sc.

    Baylor College of Medicine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

November 23, 2016

First Posted

November 29, 2016

Study Start

November 1, 2016

Primary Completion

June 1, 2019

Study Completion

June 1, 2019

Last Updated

November 25, 2020

Results First Posted

November 25, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will share

Data will be open to sharing after primary findings of study have been published

Locations